New drug combination shows promising results in treating prostate cancer
A new study by researchers from the University of Utah and led by Prof Neeraj Agarwal, demonstrated that using talazoparib, an oral poly ADP-ribose polymerase (PARP) inhibitor, marketed as Talzenna in combination with enzalutamide, a nonsteroidal antiandrogen medication, used in the treatment of prostate cancer, and marketed as Xtandi may reduce the risk of disease progression or death by 37%.
According to available data from Global Cancer Observatory, in 2020, prostrate cancer affected about 1.4 million people and resulted in over 375,000 deaths across the globe. Data from the National Cancer Institute, prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. Castration-resistant prostate cancer, or CRPC, is a late-stage prostate cancer that continues to grow despite androgen blockade.
The trial of the combination named Talapro-2, a combination of two oral medications, Talzenna and Xtandi, to treat metastatic prostate cancer, tried to assess the effectiveness of adding Talzenna to the standard treatment of Xtandi, an androgen receptor blocker that prevents male hormones from feeding cancer.
| - Metastatic prostate cancer patients living longer: Study |
| - Prostate cancer cases rising in the country: Prof Anup Kumar |
| - 106-year-old patient undergoes prostate surgery |
The clinical trial team at the Huntsman Cancer Institute played a critical role in the monitoring of participants enrolled at the institute. The researchers said.
“As a physician, I want my patients to be able to enjoy life while being treated for cancer,” says Agarwal.
“Clinical trials help us find better cancer treatments with fewer side effects. Those who are impacted by cancer can have hope that their treatment is constantly improving,” he stated.
